Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31210678 | 0.89 | KDM4E (0.49) | KDM4EALDH1A1POLBHPGDCYP1A2 | |
| SCHEMBL31210467 | 0.89 | KDM4E (0.49) | KDM4EALDH1A1POLBHPGDCYP1A2 | |
| SCHEMBL23534393 | 0.85 | KDM4E (0.46) | KDM4EALDH1A1POLBHPGDCYP1A2 | |
| SCHEMBL7326240 | 0.84 | KDM4E (0.45) | KDM4EALDH1A1POLBHPGDCYP1A2 | |
| SCHEMBL29155760 | 0.82 | KDM4E (0.43) | KDM4EALDH1A1POLBHPGDCYP1A2 | |
| SCHEMBL23571734 | 0.82 | RXFP1 (0.34) | KDM4EALDH1A1POLBHPGDRXFP1 | |
| SCHEMBL5554280 | 0.80 | KMT2A (0.49) | KDM4EALDH1A1POLBHPGDCYP1A2 | |
| SCHEMBL3499310 | 0.79 | RXFP1 (0.68) | KDM4EALDH1A1POLBHPGDCYP1A2 | |
| SCHEMBL24737463 | 0.79 | KDM4E (0.54) | KDM4EALDH1A1POLBHPGDCYP1A2 | |
| SCHEMBL12143979 | 0.79 | RXFP1 (0.52) | KDM4EALDH1A1POLBHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076460-B1 | 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12441730-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| US-20230114091-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2023279938-A1 | 2,6,8-POLYSUBSTITUTED IMIDAZO[1,2-A]PYRAZINE, AND SYNTHESIS METHOD THEREFOR AND USE THEREOF | 无锡市第二人民医院 | 2023-01-12 | — | — | WO | disclosed |
| WO-2023279938-A1 | 2,6,8-POLYSUBSTITUTED IMIDAZO[1,2-A]PYRAZINE, AND SYNTHESIS METHOD THEREFOR AND USE THEREOF | 无锡市第二人民医院 | 2023-01-12 | — | — | WO | disclosed |
| WO-2022180150-A1 | IMIDAZO[1,2-A]PYRAZINES AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2022-09-01 | — | — | WO | disclosed |
| EP-4049726-A1 | IMIDAZO[1,2-A]PYRAZINES AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2022-08-31 | — | — | EP | disclosed |
| WO-2012080228-A1 | 6-THIO-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080228-A1 | 6-THIO-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080234-A1 | SUBSTITUTED 6-IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080232-A1 | 2-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080236-A1 | 6-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080236-A1 | 6-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080232-A1 | 2-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| US-5028605-A | Antispasmodic, bronchodilators, uterine relaxants, cardiac analeptics, neurosedatives | L'UNIVERSITE DE MONTPELLIER I (FR) | 1991-07-02 | — | — | US | disclosed |
| EP-0348392-A1 | 8-ALKYLAMINOIMIDAZO[1,2-A]PYRAZINES AND DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | Université Montpellier I (FR) | 1990-01-03 | — | — | EP | disclosed |
| WO-1988004298-A1 | 8-ALKYLAMINOIMIDAZO[1,2-A]PYRAZINES AND DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230114091-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | KDM4E 61/4885ALDH1A1 1341/4885POLB 1640/4885 |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MAP2K2, BRPF3, BRDT | KDM4E 866/4885ALDH1A1 4173/4885POLB 1099/4885 |
| US-12441730-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | KDM4E 61/4885ALDH1A1 1341/4885POLB 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.